AcouSort AB (ACOU) AI Stock Analysis

• Market Cap: kr50.16M
• Dividend Yield: N/A
• Average Volume (3M): 29.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: 59.70%
• EPS Growth: 44.60%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 21,163,902
• 10 Day Avg. Volume: 27,764
• 30 Day Avg. Volume: 29,240
• PEG Ratio: 0.12
• Price to Book (P/B): 3.27
• Price to Sales (P/S): 7.79
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.4
• Revenue Forecast (FY): kr18.80M

• Rating: 47 Neutral
• Price Target: kr2.50 ▼(-5.30% Downside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is held down primarily by weak financial performance—persistent operating losses and recent multi-year cash burn—despite a low-leverage balance sheet. Technicals add downside pressure with the stock trading below major moving averages and a negative MACD. Valuation is only mildly supportive because the negative P/E reflects unprofitable operations and dividend yield is unavailable.

Positive Factors

Low Leverage / Zero Debt

Zero reported debt materially reduces refinancing and interest-rate risk, giving the company greater financial flexibility to fund R&D and commercialization. A debt-free structure supports resilience during cash burn phases and preserves optionality for strategic partnerships or targeted investments.

Recent Revenue Recovery

A 22% revenue increase in 2025 indicates improving commercial traction and demand for the platform. Sustained top-line growth, if continued, supports scale economics and validates product-market fit in target segments, improving prospects for durable margin and cash-flow improvement.

Product-Market Fit in Growing End Markets

The acoustofluidic AcouWash addresses core processing needs (washing, separation, buffer exchange) in expanding cell therapy and bioprocessing markets. Structural growth in cell therapies and lab automation can sustain demand for label-free microfluidic solutions, supporting long-term commercial opportunity.

Negative Factors

Persistent Operating Losses

Multi-year net losses indicate the core business is not yet profitable, prolonging dependence on external financing. Persistent operating deficits constrain reinvestment capacity, increase dilution risk from future raises, and make achieving sustainable profitability a multi-quarter to multi-year challenge.

Weak Cash Generation

Consistently negative operating and free cash flow undermines self-funding ability and heightens funding risk. Without reliable cash generation, the company faces recurring capital raises or partnerships to support operations, which can dilute shareholders and limit long-term strategic autonomy.

Margin Sustainability / Cost Pressure

A sharply negative gross margin in 2025 and recurring EBIT/EBITDA losses point to cost structure or pricing challenges. Persistent negative margins question scalability: unless unit economics improve, revenue growth may not translate into durable profitability or positive free cash flow.

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.

How the Company Makes Money

AcouSort AB generates revenue through the sale of its acoustic separation systems and devices to research institutions, diagnostic companies, and clinical laboratories. The company also earns income by providing custom solutions and services that leverage its proprietary technology for specific customer needs. Additionally, AcouSort may engage in partnerships and collaborations with other companies and research entities to further develop and market its technologies, which can also contribute to its revenue streams through licensing agreements or joint ventures. The company's earnings are influenced by the demand for advanced diagnostic and research tools that can offer improved efficiency and accuracy in biological sample processing.

AcouSort AB Financial Statement Overview

Summary

Financials are constrained by sustained losses and recurring cash burn (negative net income throughout 2020–2025; operating cash flow negative in 2023–2025). The balance sheet is a relative positive with zero reported debt and positive equity, but profitability and self-funding capacity remain weak despite improved 2025 revenue (+22% YoY).

Income Statement

Revenue has been volatile but improved in 2025 (+22% year over year) after a weaker 2024, which is a positive sign for demand. However, profitability remains very weak: the company has reported losses every year (net income negative across 2020–2025), and operating results are deeply negative (EBIT and EBITDA losses each year). Margins are consistently negative at the bottom line, and 2025 also shows a sharply negative gross margin, indicating cost pressure and/or one-offs that overwhelmed revenue.

Balance Sheet

The balance sheet is a relative strength: total debt is reported as zero across all periods, which materially reduces financial risk and refinancing pressure. Equity is positive each year, supporting solvency, but returns to shareholders are poor with consistently negative return on equity driven by ongoing losses. Equity levels also fluctuate significantly year-to-year, suggesting the company may be relying on equity funding to sustain operations.

Cash Flow

Cash generation is weak and inconsistent. Operating cash flow is negative in most years (notably 2023–2025), indicating the core business is not self-funding, and free cash flow is negative in multiple periods as well. While 2022 showed positive operating and free cash flow, the subsequent deterioration (large cash outflows in 2023–2025) raises funding risk and points to continued dependence on external capital if the trend persists.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.85M	4.74M	10.55M	4.96M	3.01M
Gross Profit	-14.50M	4.77M	8.39M	2.91M	548.00K
EBITDA	-14.33M	-15.89M	-16.70M	-12.86M	-11.46M
Net Income	-12.15M	-15.08M	-17.09M	-13.21M	-12.38M
Balance Sheet
Total Assets	17.89M	12.32M	34.51M	42.66M	36.56M
Cash, Cash Equivalents and Short-Term Investments	6.29M	3.57M	23.99M	33.97M	31.52M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.59M	3.86M	10.38M	22.54M	3.54M
Stockholders Equity	16.30M	8.46M	24.14M	20.11M	33.02M
Cash Flow
Free Cash Flow	0.00	-19.84M	-31.77M	2.95M	-12.23M
Operating Cash Flow	-16.78M	-18.81M	-31.56M	3.96M	-10.92M
Investing Cash Flow	-488.00K	-1.02M	-1.16M	-1.01M	-1.31M
Financing Cash Flow	18.98M	-157.00K	22.08M	0.00	35.63M

AcouSort AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Negative. The current price of 2.64 is above the 20-day moving average (MA) of 2.53, below the 50-day MA of 2.64, and below the 200-day MA of 3.01, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 41.68 is Neutral, neither overbought nor oversold. The STOCH value of 15.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPRINT	79 Outperform	kr198.37M	2.26	-264.12%	―	-17.80%	-11.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACOU	47 Neutral	kr50.16M	-3.61	-80.90%	―	59.70%	44.60%
ONCOZ	47 Neutral	kr78.54M	-5.16	-78.79%	―	―	20.55%
PILA	44 Neutral	kr57.56M	-2.50	-601.02%	―	―	―
LARK	43 Neutral	kr43.36M	-3.57	―	8.47%	-94.12%	-25.83%
EXPRS2	40 Underperform	kr24.18M	-0.50	-88.65%	―	8.46%	11.73%